| John Najim |
John Najim is currently the Chief Technical Officer at Dyne Therapeutics, Inc. Prior to his current position, he worked as an Associate Director-Manufacturing at Dyax Corp. and as the VP-Manufacturing & Process Development at Proteon Therapeutics, Inc. from 2009 to 2019. Mr. Najim holds an MBA from Bentley University and an undergraduate degree from Merrimack College. |
| Susanna G. High |
Susanna G. High is currently the Chief Operating Officer at Dyne Therapeutics, Inc. She previously worked as the Chief Operating Officer at bluebird bio, Inc. from 2016 to 2019. Prior to that, she was the SVP-Strategy & Business Integration at Alnylam Pharmaceuticals, Inc. from 2015 to 2016. From 2001 to 2007, she worked as the Director-Corporate Strategy at Millennium Pharmaceuticals, Inc. Susanna's earliest job was as a Management Consultant at Accenture LLC from 1996 to 2001. She received a graduate degree from the University of Bocconi and an MBA from MIT Sloan School of Management in 1996. |
| Jason Paul Rhodes |
Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN), Rectify Pharmaceuticals, and Generation Bio (NASDAQ: GBIO). He is also on the boards of AAVantgarde Bio, Be Biopharma, K36, and Accent Therapeutics. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020, and was previously on the boards of Third Harmonic Bio (NASDAQ: THRD), Replimune (NASDAQ: REPL), and Bicycle Therapeutics (NASDAQ: BCYC).
Previously, Jason held leadership positions at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development, and Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family. |
| Ashish Dugar |
Ashish Dugar is currently the Chief Medical Affairs Officer at Dyne Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Medical Affairs at Sarepta Therapeutics, Inc. from 2017 to 2021. Before that, he was the Vice President-Commercial Development at Intra-Cellular Therapies, Inc. from 2015 to 2017. He also held the position of Vice President & Global Head-Clinical Development at Pfizer Inc. from 2011 to 2013. Dr. Dugar holds an MBA from The Pennsylvania State University and a doctorate degree from Pennsylvania State University College of Medicine. |
| Wildon R. Farwell |
Wildon R. Farwell is currently the Chief Medical Officer at Dyne Therapeutics, Inc. Prior to this, he worked as the Global Medical Head-Medical Diseases at Biogen, Inc. from 2020 to 2021. He also worked as an Assistant Professor at Harvard Medical School. Farwell holds a graduate degree from Harvard T.H. Chan School of Public Health and a doctorate from the University of Missouri School of Medicine. |
| Catherine Stehman-Breen |
Catherine Stehman-Breen is currently the Chief Executive Officer & Director at Chroma Medicine, Inc., an Independent Director at Generation Bio Co., an Independent Director at Tenaya Therapeutics, Inc., the Director & Chief Medical Officer at Dyne Therapeutics, Inc., and an Advisor at Atlas Venture Advisors, Inc. and Atlas Venture Life Science Advisors LLC. She is also an Associate Professor at UW School of Public Health. In her former positions, Dr. Stehman-Breen served as the Chairman-United States Renal Data System at the National Institute of Diabetes & Digestive & Kidney Diseases. She was also the Vice President-Global Development at Amgen, Inc. from 2003 to 2015, the VP-Clinical Development & Regulatory Affairs at Regeneron Pharmaceuticals, Inc. from 2015 to 2017, the Chief Medical Officer at Sarepta Therapeutics, Inc. in 2017, the Chief Research & Development Officer at Obsidian Therapeutics, Inc. from 2019 to 2020, and the Chief Medical Officer at Disarm Therapeutics, Inc. from 2018 to 2019. Dr. Stehman-Breen obtained her graduate degree from the University of Washington in 1996. She completed her undergraduate degree at Colby College in 1985. She also holds graduate and doctorate degrees from The University of Chicago, which she received in 1990. |
| Oxana Beskrovnaya |
Oxana Beskrovnaya is the Chief Scientific Officer at Dyne Therapeutics, Inc. She started this position in 2021. Prior to her current role, she obtained a doctorate degree from Moscow State University Lomonosov. |
| Jonathan McNeill |
Jonathan McNeill is currently the Chief Business Officer at Dyne Therapeutics, Inc. Prior to his current position, he worked as the Associate Director-Business Development at Editas Medicine, Inc. from 2015 to 2019. Dr. McNeill received his graduate degree from the University of Pennsylvania in 2014 and his undergraduate degree from The University of North Carolina at Chapel Hill in 2007. He also holds a doctorate degree from Perelman School of Medicine. |
| Debra Feldman |
Presently, Debra Feldman holds the position of Vice President & Head-Regulatory Affairs at Dyne Therapeutics, Inc.
She previously occupied the position of Vice President-Regulatory Affairs at SAGE Therapeutics, Inc. and Senior Director-Regulatory Affairs at MediVector, Inc.
She received an undergraduate degree from the University of Massachusetts and a graduate degree from Boston University. |
| Joshua T. Brumm |
Joshua T. Brumm founded Water Street Solutions, Inc. Presently, Mr. Brumm is Chairman for Amphista Therapeutics Ltd., President, CEO, Secretary& Director at Dyne Therapeutics, Inc. and Advisor at Atlas Venture Advisors, Inc.
In the past Joshua T. Brumm held the position of Chief Operating & Financial Officer at Kaleido Biosciences, Inc., COO & CFO at Aravive, Inc. and Chief Operating & Financial Officer for Versartis, Inc. (a subsidiary of Aravive, Inc.), Chief Executive Officer at Water Street Solutions, Inc., Executive VP, Chief Financial & Accounting Officer at Pharmacyclics LLC, CFO, Senior VP & Head-Investor Relations at ZELTIQ Aesthetics, Inc. and Finance Director for Proteolix, Inc.
He received an undergraduate degree from the University of Notre Dame. |
| John G. Cox |
John G. Cox is currently the President, Chief Executive Officer & Director at Dyne Therapeutics, Inc. He is also the Chairman at Minovia Therapeutics Ltd. and a Director at Torque Therapeutics, Inc. Previously, Mr. Cox served as the Chief Executive Officer & Director at Repertoire Immune Medicines, Inc. from 2019 to 2022. He was also the Chief Executive Officer & Director at Bioverativ, Inc. from 2017 to 2018. Additionally, he served as an Independent Director at Repligen Corp. from 2013 to 2020. Mr. Cox has also held positions as a Director at Samsung Bioepis Co., Ltd., an Independent Director at Sigilon Therapeutics, Inc. from 2019 to 2023, and as a Principal at Wyeth LLC from 1993 to 2000. He was the EVP-Global Commercial & Technical Operations at Biogen, Inc. from 2016 to 2017 and a Principal at Covance Biotechnology Services, Inc. in 2003. He also worked as an Executive Vice President at Biogen Idec New Ventures, Inc. In terms of education, Mr. Cox completed his undergraduate degree at Arizona State University. He pursued his graduate studies at The California State University and obtained an MBA from the University of Michigan. |
| Carlo Incerti |
Carlo Incerti is currently the Chairman at EryDel SpA, Azafaros BV, Inversago Pharma, Inc., VectorY BV, and Numab Therapeutics AG. He is also an Independent Director at Dyne Therapeutics, Inc. and an Operating Partner at Forbion Capital Partners Management Holding BV. Additionally, he is a Member of the International Rare Diseases Research Consortium. Dr. Incerti's former positions include being the Chairman at AGC Biologics SpA and Gotham Therapeutics Corp. He also served as the Chairman at AGC Biologics SpA from 2018 to 2020. Furthermore, he held the position of Senior Vice President-Global Market Access at Genzyme Corp. from 1992 to 2018 and was the Chief Medical Officer & Senior Vice President at Genzyme Therapeutics Ltd.Dr. Incerti obtained his doctorate degree from Università degli Studi di Modena e Reggio Emilia in 1984. |
| Edward M. Hurwitz |
Edward M. Hurwitz founded Precision BioVentures LLC in 2013, where he is working as Managing Director from 2013 and Viewpoint Therapeutics, Inc. in 2014, where he is working as Chairman. Mr. Hurwitz also currently works at Rekindle Therapeutics, Inc., as Chairman, Biointervene, Inc., as Chairman, Alta BioPharma Management III LLC, as Director, MPM BioImpact, Inc, as Managing Director from 2017, MacroGenics, Inc., as Independent Director from 2004, ReCode Therapeutics, Inc., as Director, Dyne Therapeutics, Inc., as Independent Director from 2018, Protego Biopharma, Inc., as Director, Alta Embarcadero Biopharma Partners III LLC, as Manager, and Turmeric Acquisition Corp., as Chief Financial Officer. Mr. Hurwitz also formerly worked at Alta Partners Management Co. LP, as Director, FoldRx Pharmaceuticals LLC, as Director, Sunesis Pharmaceuticals, Inc., as Independent Director from 2011 to 2013, Taligen Therapeutics, Inc., as Director, CARA Therapeutics, Inc., as Independent Director from 2006 to 2014, Avid Radiopharmaceuticals, Inc., as Director, Alta Partners VIII LP, as Director from 2002 to 2014, Calistoga Pharmaceuticals, Inc., as Director, Beacon Therapeutics (USA), Inc., as Independent Director from 2012 to 2022, Alta Partners LP, as Director from 2002 to 2014, Alta Biopharma Iii LP, as Director from 2002 to 2014, and Affymetrix, Inc., as Chief Financial Officer & Senior Vice President from 1997 to 2002. Mr. Hurwitz received his undergraduate degree in 1985 from Cornell University, Masters Business Admin degree in 1990 from Haas School of Business, and graduate degree from Berkeley Law University of California. |
| David Charles Lubner |
David Charles Lubner is currently serving as an Independent Director at Arcellx, Inc., Gemini Therapeutics Sub, Inc., Cerevance, Inc., Vor Biopharma, Inc., Dyne Therapeutics, Inc., and Cargo Therapeutics, Inc. He is also a Non-Executive Director at Ichnos Sciences, Inc. and a Member at The American Institute of Certified Public Accountants. In the past, he has served as a Director at NightstaRx Ltd., Chief Financial Officer at PharMetrics, Inc., Chief Financial Officer & Senior Vice President at Tetraphase Pharmaceuticals, Inc., and Chief Financial Officer, Secretary & Executive VP at Ra Pharmaceuticals, Inc. He has also served as an Independent Non-Executive Director at Nightstar Therapeutics Ltd., Independent Director at Therapeutics Acquisition Corp., and Independent Director at Gemini Therapeutics, Inc. He holds a graduate degree from Bentley University and an undergraduate degree from Northeastern University. |
| Dirk Kersten |
Dirk Kersten is currently serving as a Director at NorthSea Therapeutics BV, an Independent Director at Dyne Therapeutics, Inc., a Director at Synox Therapeutics Ltd., and a General Partner at Forbion Capital Partners Management Holding BV. Previously, he held positions as a Director at GTx, Inc., Audion Therapeutics BV, Ascendis Pharma A, Profibrix BV, NightBalance BV, Lanthio Pharma BV, and ViCentra BV. He also served as a Managing Director at INKEF Capital BV and a Partner at Gilde Healthcare Partners, Inc. Mr. Kersten obtained a graduate degree from the University of Groningen. |
